All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

Michael DickinsonScientific Advisory Board Member

Michael DickinsonScientific Advisory Board Member

Doctor Michael Dickinson is a clinical hematologist at the Peter MacCallum Cancer Centre, Melbourne, AU, and is the Lead of the Aggressive Lymphoma Stream within the Integrated Haematology Service. Dr Dickinson obtained his medical degree at the University of Western Australia, Perth, AU, and trained as a physician in Brisbane, AU, and London, UK. He is a Julie Borschmann Fellow of Myeloma Research, University of Melbourne, Melbourne, AU.

Dr Dickinson’s research areas of interest include aggressive lymphoma, myelodysplastic syndromes, acute myeloid leukemia, and myeloma. He is a Principal Investigator in phase I/II studies, mainly in aggressive lymphoma. His research focuses on the role of epigenetic modifiers and immunotherapies in hematological malignancies and the use of eltrombopag as a supportive care agent in myeloid malignancies. Additionally, he researches novel methods of molecular analysis for patients with lymphoid malignancies.

Positions of responsibility/awards:

|||